Next Article in Journal
The Effects of Acute High-Intensity Interval Training on Hematological Parameters in Sedentary Subjects
Previous Article in Journal
The Bronchiectasis Toolbox—A Comprehensive Website for the Management of People with Bronchiectasis
Previous Article in Special Issue
Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell Carcinoma
Article Menu

Export Article

Open AccessFeature PaperReview
Med. Sci. 2017, 5(2), 14; doi:10.3390/medsci5020014

Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs)

1
Ludwig-Maximilians-University (LMU), Department of General, Visceral, and Transplantation Surgery, Hospital of the LMU Munich, Munich 81377, Germany
2
Ludwig-Maximilians-University (LMU), Department of Internal Medicine III, Hospital of the University of Munich, Munich 81377, Germany
*
Author to whom correspondence should be addressed.
Received: 19 April 2017 / Revised: 11 June 2017 / Accepted: 11 June 2017 / Published: 19 June 2017
(This article belongs to the Special Issue Gene Therapy and Cancer: Current Developments)
View Full-Text   |   Download PDF [769 KB, uploaded 19 June 2017]   |  

Abstract

The diagnosis of pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis, in particular, when patients present with unresectable disease. While significant progress has been made in understanding the biology of PDAC, this knowledge has not translated into a clear clinical benefit and current chemotherapeutic strategies only offer a modest improvement in overall survival. Accordingly, novel approaches are desperately needed. One hypothesis that could—at least in part—explain the desolate response of PDAC to chemotherapy is the so-called cancer stem cell (CSC) concept, which attributes specific traits, such as chemoresistance, metastatic potential and a distinct metabolism to a small cellular subpopulation of the whole tumor. At the same time, however, some of these attributes could make CSCs more permissive for novel therapeutic strategies with compounds that are already in clinical use. Most recently, several publications have tried to enlighten the field with the idea of repurposing established drugs for antineoplastic use. As such, recycling drugs could present an intriguing and fast-track method with new therapeutic paradigms in anti-cancer and anti-CSC treatments. Here, we aim to summarize important aspects and novel findings of this emerging field. View Full-Text
Keywords: pancreatic ductal adenocarcinoma; cancer stem cells; repurposing; therapeutics; metabolism pancreatic ductal adenocarcinoma; cancer stem cells; repurposing; therapeutics; metabolism
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Renz, B.W.; D’Haese, J.G.; Werner, J.; Westphalen, C.B.; Ilmer, M. Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs). Med. Sci. 2017, 5, 14.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Med. Sci. EISSN 2076-3271 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top